IRWD IRONWOOD PHARMACEUTICALS INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 1446847 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY18.1%
TTM net income YoY424.1%
TTM EPS YoY400.0%
Revenue 3-yr CAGR-2.5%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin62.9%
Net margin37.4%
FCF margin—
EBITDA margin63.2%
Returns
ROE—
ROA43.6%
ROIC (approx.)—
Asset turnover1.17x
Leverage & solvency
Liabilities / assets133.4%
Debt / equity—
Current ratio6.51x
Interest coverage8.28x
Cash quality & payout
Operating cash flow / net income1.37x
Accruals ratio-16.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q42025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q42024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $133.04M | $113.04M | $106.51M | $47.71M | $122.06M | $85.24M | $41.14M | $90.55M |
| R&D expense | $28.35M | $22.42M | $21.94M | $21.86M | $22.47M | $23.37M | $27.43M | $25.39M |
| SG&A expense | $11.55M | $11.31M | $12.03M | $19.29M | $21.91M | $16.80M | $24.26M | $33.59M |
| Operating income | $93.13M | $79.31M | $72.57M | $6.80M | $75.48M | $45.32M | -$29.11M | $31.49M |
| Interest expense | $6.20M | $7.20M | $9.14M | $7.89M | $8.43M | $8.36M | $8.07M | $8.91M |
| Pretax income | $87.60M | $73.73M | $65.17M | $455,000 | $68.02M | $37.82M | -$36.27M | $24.00M |
| Income tax | $27.76M | $22.44M | $24.40M | $2.73M | $27.94M | $14.22M | $1.11M | $21.74M |
| Net income | $59.84M | $51.29M | $40.77M | -$2.28M | $40.08M | $23.60M | -$37.39M | $2.26M |
| EBITDA | $93.59M | $79.76M | $73.02M | $6.48M | $75.96M | $45.79M | -$28.63M | $31.16M |
| EPS (basic) | 0.36 | 0.31 | 0.25 | -0.01 | 0.25 | 0.15 | -0.23 | — |
| EPS (diluted) | 0.36 | 0.31 | 0.24 | -0.01 | 0.23 | 0.14 | -0.23 | — |
| Weighted avg. shares (diluted) | 168.18M | 167.18M | 166.69M | — | 177.76M | 176.84M | 160.97M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $86.38M | $79.13M | $220.47M | $215.46M | $140.41M | $92.85M | $108.48M | $88.56M |
| Receivables | $132.72M | $112.73M | $105.84M | $46.74M | $120.37M | $86.17M | $39.77M | $81.89M |
| Current assets | $225.99M | $199.20M | $332.29M | $274.18M | $273.84M | $191.75M | $160.58M | $182.37M |
| PP&E, net | $2.66M | $2.91M | $3.17M | $3.41M | $3.67M | $3.93M | $4.26M | $4.50M |
| Intangibles | $1.43M | $1.63M | $1.84M | $2.04M | $2.25M | $2.45M | $2.66M | $2.86M |
| Total assets | $290.59M | $285.13M | $434.57M | $396.90M | $396.06M | $342.95M | $327.21M | $350.91M |
| Current liabilities | $34.73M | $32.85M | $236.31M | $242.22M | $242.50M | $232.53M | $48.10M | $38.85M |
| Long-term debt | — | — | — | — | $199.51M | $199.33M | $199.16M | $198.99M |
| Total debt | — | — | — | — | $199.51M | $199.33M | $199.16M | $198.99M |
| Total liabilities | $387.79M | $446.97M | $651.71M | $658.74M | $660.22M | $651.11M | $661.27M | $652.24M |
| Shareholders' equity | -$97.19M | -$161.84M | -$217.14M | -$261.83M | -$264.16M | -$308.16M | -$334.05M | -$301.33M |
| Net debt | — | — | — | — | $59.10M | $106.48M | $90.68M | $110.43M |
| Shares outstanding | 165.55M | 165.24M | 164.61M | 163.06M | 162.68M | 162.43M | 161.81M | 160.21M |
| Cash flow statement | ||||||||
| Operating cash flow | $67.40M | $58.28M | $5.12M | $74.58M | $47.58M | -$15.07M | $19.95M | $15.21M |
| Capital expenditure | — | — | — | -$1,000 | $2,000 | $2,000 | $31,000 | $0 |
| Free cash flow | — | — | — | $74.58M | $47.58M | -$15.07M | $19.92M | $15.21M |
| Investing cash flow | — | — | — | $1,000 | -$2,000 | -$2,000 | -$31,000 | $0 |
| Financing cash flow | -$60.00M | — | — | $122,000 | $0 | $88,000 | $6,000 | -$14.89M |
| Depreciation & amortization | $459,000 | $457,000 | $443,000 | -$321,000 | $475,000 | $467,000 | $479,000 | -$326,000 |
| Stock-based compensation | $4.29M | $3.24M | $3.65M | $3.82M | $3.61M | $4.52M | $5.29M | $4.57M |
Free plan shows the latest 8 periods; Pro shows all 67 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.